# Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

> **NCT03610438** · PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 76 (estimated)

## Conditions studied

- Acute Lymphoid Leukemia

## Interventions

- **DRUG:** Inotuzumab Ozogamicin (IO)
- **DRUG:** Inotuzumab Ozogamicin (IO)

## Key facts

- **NCT ID:** NCT03610438
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-30
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610438, "Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03610438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*